The objective of this study is to compare the real-world effectiveness of BFC and FSC in asthma patients new to ICS/LABA combination therapy in a population of U.S. health plan enrollees.
A U.S. retrospective database analysis evaluating the comparative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol among asthma patients
Study Type
OBSERVATIONAL
Enrollment
6,086
Rate of asthma exacerbations
The rate is defined as the total number of asthma exacerbations for all patients in the cohort divided by the total number of person years. An asthma exacerbation is defined as any of three conditions: Asthma related inpatient hospitalization or Asthma related emergency department visit or Oral corticosteroid use.
Time frame: 12 months
Asthma Related Inpatient Hospitalizations
Time frame: 12 months
Asthma Related Emergency Department visits
Time frame: 12 months
Use of Oral Corticosteroids (OCS)
A pharmacy claim for any of the OCS medications
Time frame: 12 months
Asthma controller medication use (SABA, ICS, LABA, LTRA, XOLAIR, THEOPHYLLINE)
Asthma controller use (0 vs. 1 and total number of fills for each).
Time frame: 12 months
Asthma Related Healthcare Utilization
Asthma Related Healthcare Utilization: Outpatient/office visits, Inpatient length of stay, ICU admission and length of stay.
Time frame: 12 months
Asthma Related Healthcare costs
Asthma Related Healthcare costs (plan paid, patient paid and plan + patient paid)costs of all Asthma related medication and Asthma related outpatient/office, ED and Inpatient visits.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.